25 th annual roth conference nyse mkt btx n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
25 th Annual ROTH Conference NYSE MKT: BTX PowerPoint Presentation
Download Presentation
25 th Annual ROTH Conference NYSE MKT: BTX

Loading in 2 Seconds...

play fullscreen
1 / 36

25 th Annual ROTH Conference NYSE MKT: BTX - PowerPoint PPT Presentation


  • 167 Views
  • Uploaded on

25 th Annual ROTH Conference NYSE MKT: BTX. March, 2013. Forward Looking Statements.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about '25 th Annual ROTH Conference NYSE MKT: BTX' - darrin


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
forward looking statements
Forward Looking Statements

The matters discussed in this presentation include forward looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the success of BioTime in developing new stem cell products and technologies; results of clinical trials of BioTime products; the ability of BioTime and its licensees to obtain additional FDA and foreign regulatory approval to market BioTime products; competition from products manufactured and sold or being developed by other companies; the price of and demand for BioTime products; and the ability of BioTime to raise the capital needed to finance its current and planned operations. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. As actual results may differ materially from the results anticipated in these forward-looking statements they should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

the health care challenge opportunity
The Health Care Challenge & Opportunity
  • A global tsunami of health care costs from ineffectiveness of drugs to treat chronic degenerative disease (CDD)
  • CDD due to lack of cellular regeneration
  • 80% Americans have CDD of aging
  • 50% of Americans have two CDDs
  • 95% costs in aging is CDD
the health care challenge opportunity1
The Health Care Challenge & Opportunity
  • Progressive evolution of new & more interventional products over past four decades

Recombinant DNA Technology

  • Regenerative Medicine

Monoclonal Antibodies

  • 1998 – Embryonic Stem Cells allowing for the first time in the history of medicine the manufacture of all human cellular components
  • 2001 – U.S. Federal funding restriction (reversed in 2009)
  • 2010 – 1sthES Clinical trial
  • Future – 1st $B product
  • 1975 - Hybridoma technology developed
  • 1997- First $B Product Rituximab
  • Advances in Mab Engineering
  • Today, eight of the 20 best-selling biotechnology drugs in therapeutic monoclonal antibodies
  • > 200 clinical trials
  • Current Global Market $44 B
  • 1974 – Gene cloning technology developed
  • 1976 - Moratorium on rDNA research initiated led to established guidelines on rDNA research
  • 1989 – First $B product EPO
  • Today, products from the use of rDNA technology are ubiquitous
  • >140 clinical trials
  • Current Global Market $75 B
the biotime opportunity
The BioTime Opportunity
  • Consolidating key stem cell assets
  • - ES Cell International
  • - Geron stem cell assets
  • - HyStem hydrogels
  • Integration with PureStem technology
  • Focus on near-term products
  • Significant clinical milestones for 2013
purestem manufacturing technology
PureStem Manufacturing Technology
  • Human embryonic progenitor (hEP)
  • cell lines: > 200 diverse cell types isolated
  • Diversity
  • Precise identity
  • Purity
  • Scalability
  • Patents pending

Kidney

Smooth Muscle

Skeletal Muscle

Blood/Brain

Barrier

renevia tm cell delivery device
ReneviaTM – Cell Delivery Device
  • Injectable, biocompatible, and biodegradable

Low COGs, Stable Product, Potential Widespread Applications

Cells in Renevia Matrix (Cross-linked Collagen and Hyaluronate)

hystem hydrogels competitive advantages
HyStem Hydrogels – Competitive Advantages

Injectable

Stays as liquid for ~ 20 minutes

Polymerizes safely in vivo

Supports survival of cells and 3-D structure

Multiple Formulations

Heparin-mediated Slow Release

Cast Hydrogel

Cells in Sponge

3-D Lattices

Durable Films

renevia tm development
ReneviaTM – Development
  • Indication: As a delivery matrix for autologous adipose derived cells to correct subcutaneous lipoatrophy arising from trauma, oncologic resection, or congenital defect.
  • 3 Phase Clinical Evaluation ofReneviaTM
  • • Phase 1: Safety - open label, ReneviaTM only, subcutaneous injection, 10 subjects, 4 week follow up.
  • • Phase 2: Treatment Effect - open label, ReneviaTM+ ADSCs, 15 patients, 3-6 months follow up.
  • • Phase 3: Pivotal - randomized, controlled, evaluator blind, non-inferiority, ReneviaTM+ ADSCs vs. Cell-Assisted Lipotransfer, # of patient per group TBD, 6 months follow up.
  • • Primary endpoints: Aesthetic Improvement Score & photo review
  • • Secondary endpoint:Change in subcutaneous defect volume
  • • Single Site: The Stem Center, Palma de Mallorca, Spain
renevia tm a cell delivery device
ReneviaTM – A Cell Delivery Device
  • Adipose tissue restoration with autologousASCs
  • Medical device (CE Mark in the EU then CBER/CDRH)
  • Outsource cGMP manufacture
  • Near-term opportunity, low cost for approval

ReneviaTMRegulatory Strategy

  • Expected ReneviaTMCE Mark in 2015

ReneviaTMTimeline

Treatment Effect Clinical Trial Initiated

Complete cGMP

Manufacture

CE Mark Renevia™

Final Dossier Submission

Safety Clinical Trial Initiated

Pivotal Clinical Trial Initiated

ISO 13485 Certification

Q4

Q1

Q2

Q3

Q4

Q1

Q2

Q3

Q4

Q1

2012

2013

2014

2015

potential renevia tm applications
Potential ReneviaTM Applications

Potential

Applicable

U.S. Market

Potential

Utility

  • Heart Disease ✔165 B
  • Alzheimer’s ✔ 69 B
  • Diabetes ✔ 92 B
  • Stroke ✔ 28 B
  • Renal Failure ✔ 33 B

Regen. Med. (2008) 3(3), 351–363

subsidiaries

OncoCyte Corporation

Cancer diagnostics and anti-cancer therapies

  • Cell Cure Neurosciences Ltd.

Age-related macular degeneration (AMD)

Subsidiaries
  • OrthoCyte Corporation

Cartilage repair

  • ReCyte Therapeutics, Inc.

Age-related vascular disorders

  • ES Cell International PTE Ltd.

Clinical-grade master stem cell banks

  • LifeMap Sciences, Inc.

Stem cell data base and research products

  • BioTime Acquisition Corp..
    • Expected Contribution of Geron and BioTime Assets
oncocyte corporation panc dx tm
OncoCyte Corporation- PanC-DxTM
  • Screening in asymptomatic patients is the largest market opportunity

PanC-DxTM

  • Pan diagnostic to detect the presence of various human cancers, including cancers of the breast, lung, bladder, uterus, stomach, and colon, during routine check-ups using a low-cost antibody-based blood test.
  • mAb production for seven antigens in process
  • Specificity of >50 mAbscharacterized
  • Dynamic testing for use in ELISA and point of care formats currently underway.
  • Initially develop and seek regulatory approval of PanC-DxTMin Europe
  • Expected launch in 2014
panc dx tm cancer diagnostic
PanC-DxTM Cancer Diagnostic
  • CE Mark (EU) then CDRH/OIVD (U.S.)
  • Near-term opportunity, low cost for approval

Regulatory Strategy

Timeline leading to 2014 launch

Antibody Screening

Marker Validation

Final Kit Developed

CE Mark

Antibody Production

Patient Study Completion

Q4

Q3

Q3

Q3

Q3

Q1

Q2

Q1

Q2

Q1

Q2

Q4

Q4

Q4

2013

2011

2012

2014

subsidiaries1

OncoCyte Corporation

Cancer diagnostics and anti-cancer therapies

  • Cell Cure Neurosciences Ltd.

Age-related macular degeneration (AMD)

Subsidiaries
  • OrthoCyte Corporation

Cartilage repair

  • ReCyte Therapeutics, Inc.

Age-related vascular disorders

  • ES Cell International PTE Ltd.

Clinical-grade master stem cell banks

  • LifeMap Sciences, Inc.

Stem cell data base and research products

  • BioTime Acquisition Corp..
    • Expected Contribution of Geron and BioTime Assets
cell cure neurosciences ltd
Cell Cure Neurosciences Ltd.
  • OpRegen® – RPE Cells for the Treatment of AMD
  • 7.3 million have early stage dry AMD in US
  • Any effective treatment expected to achieve blockbuster sales
  • OpRegen® – Suspension of retinal pigment epithelial (RPE) cells for dry age-related macular degeneration (AMD)
  • OpRegen® Plus – Matrix bound RPE cells for dry AMD
  • Partnered with TEVA
cell cure neurosciences ltd1
Cell Cure Neurosciences Ltd.
  • Planned IND in 2013/2014
  • Phase I/IIa Study of hESC-RPE in Progressive Dry-Form Age-Related Macular Degeneration (12 patients, 1 year follow up time, single doses)
  • Primary endpoint: Safety
  • Secondary endpoint: Efficacy
    • • Visual Acuity
    • • Maintenance of graft size over serial measurements (graft survival)
    • • Reduced expansion of geographic atrophy in grafted sites vs. non-
    • grafted sites (in the same eye)
    • • Perimetry- extent and depth of central scotomata
    • • Single site: Hadassah, Israel
  • Duration (enrollment and follow up): 18 months
subsidiaries2

OncoCyte Corporation

Cancer diagnostics and anti-cancer therapies

  • Cell Cure Neurosciences Ltd.

Age-related macular degeneration (AMD)

Subsidiaries
  • OrthoCyte Corporation

Cartilage repair

  • ReCyte Therapeutics, Inc.

Age-related vascular disorders

  • ES Cell International PTE Ltd.

Clinical-grade master stem cell banks

  • LifeMap Sciences, Inc.

Stem cell data base and research products

  • BioTime Acquisition Corp..
    • Expected Contribution of Geron and BioTime Assets
orthocyte corporation
OrthoCyte Corporation
  • Developing regenerative therapeutics for orthopedic applications
  • Cartilage cannot regenerate on its own
  • Osteoarthritis and spinal disc degeneration have a significant impact on mobility and health
    • > 26 million people in U.S. and growing
  • Drug treatments target the reduction of pain and inflammation as opposed to repairing tissue
  • Studies in animal models of IVD disease underway
    • Non-hypertrophic progenitors
    • Off the shelf approach
subsidiaries3

OncoCyte Corporation

Cancer diagnostics and anti-cancer therapies

  • Cell Cure Neurosciences Ltd.

Age-related macular degeneration (AMD)

Subsidiaries
  • OrthoCyte Corporation

Cartilage repair

  • ReCyte Therapeutics, Inc.

Age-related vascular disorders

  • ES Cell International PTE Ltd.

Clinical-grade master stem cell banks

  • LifeMap Sciences, Inc.

Stem cell data base and research products

  • BioTime Acquisition Corp..
    • Expected Contribution of Geron and BioTime Assets
regenerative medicine
Regenerative Medicine

Human embryonic stem (hES) for limited allogeneic applications

Twin strategies for cell transplantation

• Sites behind the blood brain barrier

• Sites behind synovial membranes

• Cells targeting tumors for destruction

Human induced pluripotent stem (iPS) cells for auto-logous transplantation

• Vascular disease

recyte therapeutics inc
ReCyte Therapeutics, Inc.

RCX-VP01 for Age-Related Vascular Insufficiency

  • American Heart Association Report on Heart Disease and Stroke Statistics:
  • 2011 Update
  • Cardiovascular Disease (CVD)
    • Prevalence:
    •  82,600,000 American adults (>1 in 3) with 1 or more types of CVD
    •  2200 deaths from CVD per day; average life expectancy shortened 7 years
  • Stroke (Cerebrovascular Disease)
    • Incidence:
    •  800,000 new (77%) or recurrent (23%) strokes per year
    •  1 of every 18 deaths in U.S. in 2007
  • Healthcare Impact and Cost:
    •  $286 billion total direct and indirect costs of CVD and stroke in U.S. in 2007
    • nearly 7 million inpatient cardiovascular operations and procedures in 2007
subsidiaries4

OncoCyte Corporation

Cancer diagnostics and anti-cancer therapies

  • Cell Cure Neurosciences Ltd.

Age-related macular degeneration (AMD)

Subsidiaries
  • OrthoCyte Corporation

Cartilage repair

  • ReCyte Therapeutics, Inc.

Age-related vascular disorders

  • ES Cell International PTE Ltd.

Clinical-grade master stem cell banks

  • LifeMap Sciences, Inc.

Stem cell data base and research products

  • BioTime Acquisition Corp..
    • Expected Contribution of Geronand BioTime Assets
lifemap sciences inc
LifeMap Sciences, Inc.

The leading human gene database

  • • Used in more than 1,000 institutions world-wide including academia, research hospitals, patent offices, and the leading biotech and pharma
  • • More than 12 Million page visits/year by hundreds of thousands of unique users
  • • 30% usage growth in the past 12 months
  • • Consistently leads in top positions for gene search results in Google
lifemap bioreagents
LifeMapBioReagents
  • >12 Million page hits/yr
  • BioTime Products
  • Third Party Products

Cells

> 1,000 USCN

Antibody kits

>1,000 Prospec-

TanyTechnogene

Proteins

Diseases

Genes

  • Near-term Revenue
  • Seed for Future Royalties
  • All online
  • % of Sales
  • Powerful Marketing Platform
subsidiaries5

OncoCyte Corporation

Cancer diagnostics and anti-cancer therapies

  • Cell Cure Neurosciences Ltd.

Age-related macular degeneration (AMD)

Subsidiaries
  • OrthoCyte Corporation

Cartilage repair

  • ReCyte Therapeutics, Inc.

Age-related vascular disorders

  • ES Cell International PTE Ltd.

Clinical-grade master stem cell banks

  • LifeMap Sciences, Inc.

Stem cell data base and research products

  • BioTime Acquisition Corp..

Contribution of Geron and BioTime Assets

biotime acquisition corp
BioTime Acquisition Corp.
  • What Geron Contributes and Receives…

Terms subject to closing

  • Geron will contribute:
  • IP and tangible assets related to hES programs
  • Phase 1 trials in acute spinal cord injury & T’ase vaccine
  • IP and sublicense to autologous cellular immunotherapy program
  • Interests in non-therapeutic applications
    • including products developed and sold by GE Heathcare
  • Geron receives:
  • Shares in BAC (approx 21.4% interest)
  • Royalties on sale of products using Geron patents
  • Shares will be distributed by Geron to their shareholders
  • (following closing)
biotime acquisition corp1
BioTime Acquisition Corp.
  • What BioTime Contributes and Receives…

Terms subject to closing

  • BioTime will contribute to BAC:
  • $5 million in cash (committed through a private investor)
  • 8.9 MM in BioTime Common Stock to be held by BAC
  • 8 million BioTime warrants
    • At closing, to be distributed by BAC to Geron stockholders
  • Minority equity interest in OrthoCyte and Cell Cure
  • Rights to use certain BioTime cell lines
  • BioTime receives:
  • Shares in BAC (Approx. 71.6% interest in BAC)
  • 3.15 MM Warrants in BAC
biotime acquisition corp2
BioTime Acquisition Corp.
  • Stem Cell Assets Being Contributed from Geron
biotime acquisition corp3
BioTime Acquisition Corp.
  • Stem Cell Assets Being Contributed from Geron

>400 issued & pending patent applications worldwide including:

• Feeder-free culture of hPS cells

• hES-derived dendritic cells for treating cancer

• TGFbeta inhibitors & Neural

• RNA isolation from hPS cells or derivatives

• Feeder free hPS cells in drug screening

• Medium for hPS cell culture

• hPS-derived hepatocytes

• Dopaminergic neurons from hPS cells

• hPS cell-specific genetic toxicity

• Selective antigen expression on hPS cells

current product pipeline
Current Product Pipeline

Preclinical

Phase I

Phase II

Phase III

Market

Partner

Hextend

Research Products/Database

HyStem®Hydrogel Products

2014-2015

Renevia

2014

PanC-DxTM

Teva

2013

OpRegen

OTX-CP07

RCX-VP01

biotime nyse mkt btx
BioTime (NYSE MKT: BTX)

A Technological Leader with Revenue, Low Burn Rate and Near-term Product Opportunities

  • $4.4MM cash of 12/31/12
  • Raised additional $16.3 million to date in 2013
  • Approx. $10MM in investments held by our subsidiaries

Key Statistics:

  • Revenue of $3.9MM in 2012
  • Avg. qtrly burn rate of $4.9MM per quarter
  • No debt
  • Market Cap approx. $240MM as of 3/15/13

Major Shareholders:

17.5%

16.1%

9.2%

46.7%

Greenbelt/Greenway/

Al Kingsley (Chairman)

Individual Investor

Insiders

& LT Investors

Broadwood Capital

(Neal Bradsher, Director)

BioTime shareholder base with significant long term investors

biotime s key milestones
BioTime’s Key Milestones
  • Next 12 months…
  • Initiation ofHyStem ® -Rxclinical trial
  • IND filing of OpRegen for AMD
  • PanC-Dx patient study
  • Corporate partnering and collaborations
  • Increased revenue from LifeMapBioReagents
summary
Summary
  • >200 purified human cell types manufactured for the first time
  • Leading patent position
  • Emphasis on near-term products:

- ReneviaTM

- PanC-DxTM

- LifeMapBioReagents

  • Longer–term first-in-class stem cell-based therapeutics for currently incurable degenerative diseases
  • Subsidiaries focused on specific disease areas

Positioned to Lead the Commercialization of Pluripotency in Regenerative Medicine

Alameda, California Headquarters

thank you
Thank You

Michael West, Ph.D.

CEO

Pete Garcia

CFO

510-521-3390

pgarcia@biotimemail.com